News

Zealand Pharma says obesity drug deal with Roche will help it stay independent
The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...
Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes
Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...
MedCity News6d
Roche Commits to $50B in U.S. Manufacturing and R&D Investments as Pharma Tariffs Loom
Roche said it will expand existing sites and construct new U.S. manufacturing and R&D infrastructure in areas such as gene ...
Fierce Pharma4d
Roche moves to mitigate US tariff impact amid discussions with global governments
Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...
GEN - Genetic Engineering and Biotechnology News6d
Roche Commits $50B to U.S. Manufacturing, R&D as Tariffs Loom
Roche projected that its $50 billion manufacturing investment, to include R&D operations, will generate 1,000 jobs at the ...
Pharmabiz2d
Zealand Pharma begins patient enrolment in phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
Copenhagen, Denmark Saturday, April 26, 2025, 18:00 Hrs [IST] ...
Seeking Alpha5d
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
Enrollment and randomization in ZUPREME-1 was completed in three months. In March 2025, Zealand Pharma and Roche entered a collaboration and license agreement to co-develop and co-commercialize ...